The Efficacy of Viral Capsid Inhibitors in Human Enterovirus Infection and Associated Diseases
Pp. 22-40 (19)
Shin-Ru Shih, Gary Brewer, Peng-Nien Huang, Kuo-Feng Weng, Chin Li, Hongtao Wang, Tzu-Chun Chen and Mei-Ling Li
Enteroviruses are members of picornavirus family which causes diverse
and severe diseases in humans and animals. Clinical manifestations of enterovirus
infections include fever, hand, foot, and mouth disease, and herpangina. Enteroviruses
also cause potentially severe and life-threatening infections such as meningitis,
encephalitis, myocarditis, polio-like syndrome, and neonatal sepsis. With the
emergence of enterovirus all over the world as the major causative agent of HFMD
fatalities in recent years and in the absence of any effective anti-enteroviral
therapy, there is clearly a need to find a specific antiviral therapy. Steps such as
viral attachment, uncoating, viral RNA replication, and protein synthesis in the
replication cycle can serve as potential targets for antiviral agents. Agents targeted
at viral protein 1 (VP1), a relatively conserved capsid structure mediating viral
adsorption and uncoating process, is of great potential to be anti-enterovirus drugs.
Recently, considerable efforts have been made in the development of antiviral
compounds targeting the capsid protein of enterovirus. This review summarizes the
development of small molecules targeting enteroviral capsid protein as effective
Enterovirus, capsid protein, antiviral therapy.
Research Center for Emerging Viral Infections, Chang-Gung University, Taiwan.